Report Detail

Request for Sample of this report

Other Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM2806706
    • |
  • 13 April, 2023
    • |
  • Global
    • |
  • 85 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Other

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
According to our (Global Info Research) latest study, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size was valued at USD 1367.7 million in 2022 and is forecast to a readjusted size of USD 14630 million by 2029 with a CAGR of 40.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
This report is a detailed and comprehensive analysis for global Duchenne Muscular Dystrophy (DMD) Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Duchenne Muscular Dystrophy (DMD) Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb and Italfarmaco and etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Duchenne Muscular Dystrophy (DMD) Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Exondys
Emflaza
Translarna
Market segment by Application
Hospitals
Clinics
Home Care
Market segment by players, this report covers
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Duchenne Muscular Dystrophy (DMD) Therapeutics, with revenue, gross margin and global market share of Duchenne Muscular Dystrophy (DMD) Therapeutics from 2018 to 2023.
Chapter 3, the Duchenne Muscular Dystrophy (DMD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Duchenne Muscular Dystrophy (DMD) Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Duchenne Muscular Dystrophy (DMD) Therapeutics.
Chapter 13, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Duchenne Muscular Dystrophy (DMD) Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Duchenne Muscular Dystrophy (DMD) Therapeutics by Type
    • 1.3.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type in 2022
    • 1.3.3 Exondys
    • 1.3.4 Emflaza
    • 1.3.5 Translarna
  • 1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application
    • 1.4.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospitals
    • 1.4.3 Clinics
    • 1.4.4 Home Care
  • 1.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size & Forecast
  • 1.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region, (2018-2029)
    • 1.6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.6 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Sarepta Therapeutics
    • 2.1.1 Sarepta Therapeutics Details
    • 2.1.2 Sarepta Therapeutics Major Business
    • 2.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
    • 2.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
  • 2.2 PTC Therapeutics
    • 2.2.1 PTC Therapeutics Details
    • 2.2.2 PTC Therapeutics Major Business
    • 2.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
    • 2.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 PTC Therapeutics Recent Developments and Future Plans
  • 2.3 Pfizer
    • 2.3.1 Pfizer Details
    • 2.3.2 Pfizer Major Business
    • 2.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
    • 2.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Pfizer Recent Developments and Future Plans
  • 2.4 Bristol-Myers Squibb
    • 2.4.1 Bristol-Myers Squibb Details
    • 2.4.2 Bristol-Myers Squibb Major Business
    • 2.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
    • 2.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 2.5 Italfarmaco
    • 2.5.1 Italfarmaco Details
    • 2.5.2 Italfarmaco Major Business
    • 2.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
    • 2.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Italfarmaco Recent Developments and Future Plans
  • 2.6 Santhera Pharmaceuticals
    • 2.6.1 Santhera Pharmaceuticals Details
    • 2.6.2 Santhera Pharmaceuticals Major Business
    • 2.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
    • 2.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Santhera Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Revenue
    • 3.2.2 Top 3 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2022
    • 3.2.3 Top 6 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2022
  • 3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Region Footprint
    • 3.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
  • 6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
  • 6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
    • 6.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)
    • 6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
  • 7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
  • 7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
    • 7.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.3 France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2018-2029)
    • 8.3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.5 India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
  • 9.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
  • 9.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
    • 9.3.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
  • 11.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
  • 11.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain
  • 12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis
  • 12.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Midstream Analysis
  • 12.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Duchenne Muscular Dystrophy (DMD) Therapeutics . Industry analysis & Market Report on Duchenne Muscular Dystrophy (DMD) Therapeutics is a syndicated market report, published as Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,780.52
    		4,170.78
    		5,561.04
    		3,246.84
    		4,870.26
    		6,493.68
    		541,314.00
    		811,971.00
    		1,082,628.00
    		289,988.40
    		434,982.60
    		579,976.80
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo